<p>ImmunoMind is a UC Berkeley SkyDeck alumnus company. ImmunoMind helps biotech companies understand crucial drug-human interactions, and transform the biodata chaos into more effective immunotherapies.</p>

ImmunoMind is a UC Berkeley SkyDeck alumnus company. ImmunoMind helps biotech companies understand crucial drug-human interactions, and transform the biodata chaos into more effective immunotherapies.

TechBio Founders #24: Using AI and multi-omics to predict the efficacy of immunotherapies with Vadim Nazarov, CEO at ImmunoMind

#TechBio is changing the world and the world needs to know more about it and the most disruptive companies who want to enable humanity to face up to its next challenges as a species, from fighting genetically transmitted diseases and pandemics to preventing ageing and climate change. In this podcast, we are featuring founders, investors, university professor or tech advisers sharing with us their unique view on the challenges and opportunities behind the Bioeconomy. This podcast is produced by Next Sequence, a venture capital fund focused on supporting globally the #TechBio ecosystem, from founders to investors.

Share TechBio Founders #24: Using AI and multi-omics to predict the efficacy of immunotherapies with Vadim Nazarov, CEO at ImmunoMind

Sign up to save your podcasts

TechBio Founders #24: Using AI and multi-omics to predict the efficacy of immunotherapies with Vadim Nazarov, CEO at ImmunoMind

TechBio Founders #24: Using AI and multi-omics to predict the efficacy of immunotherapies with Vadim Nazarov, CEO at ImmunoMind